BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance LOUISVILLE, Ky., October 30, 2026 — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2026, and increased full year 2026 Revenue and Adjusted EBITDA 1 guidance. Third Quarter 2026 Financial Highlights (note: On March 30, 2026, BrightSpring completed the divestiture of the Community Living business and, as such, all financial results provided pertain to continuing operations) • Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third quarter of 2025 • Gross profit of $519 million, up 32.3% compared to $392 million in the third quarter of 2025 • Net income from continuing operations of $101 million compared to $38 million in the third quarter of 2025 • Adjusted EBITDA 1 of $228 million, up 42.0% compared to $160 million in the third quarter of 2025 • Leverage of 1.79x as of September 30, 2026, compared to leverage of 2.15x on June 30, 2026 "Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. "We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform. As we progress through 2026, we believe that BrightSpring is well -positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond." 1 Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP. Key Financials 2
1 Adjusted EBITDA and Segment EBITDA are non-GAAP financial measures. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA and Segment EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP. 2 Financial tables may not foot due to rounding. 3 Effective July 1, 2026, the Company realigned its Rehab in Motion business from the Rehab Care sub-segment to the Home Health Care sub-segment to reflect how the business is managed. Prior period sub-segment information has been recast to conform to the current presentation. The change did not affect consolidated company or segment results. The impact on prior periods was not material. 2
For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:
Pharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to 24.1% growth
Provider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% growth
Total Adjusted EBITDA 3 of $850 million to $860 million, or 37.6% to 39.3% growth
The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026
3A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
The Company will host a conference call today, October 30that 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required toregister online.
A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website athttps://ir.brightspringhealth.com/. The Company has posted supplemental information on the third quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page.
BrightSpring Health Services provides complementary home- and community-based health solutions for medically complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to approximately 500,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating
The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward- looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
our inability to maintain relationships with existing patient referral sources or establish new referral sources;
changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;
cost containment initiatives of third-party payors, including post-payment audits;
the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;
changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;
our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;
changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;
changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;
reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;
compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;
limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;
delays in collection or non-collection of our accounts receivable, particularly during the business integration process;
failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;
our ability to identify, successfully complete and manage acquisitions, joint ventures, divestitures and other significant transactions and strategic initiatives;
maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;
contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;
effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;
security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;
various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;
our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;
factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;
inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;
the significant interests of KKR Stockholder may conflict with our stockholders’
significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and
The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.
For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website atwww.sec.gov.
This press release contains “non-GAAP financial measures,” including “EBITDA,” “Segment EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.
Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS are non-GAAP measures of our financial performance and should not be considered as an alternative to net income as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.
Management defines EBITDA as net income from continuing operations before income tax expense, interest expense, net and depreciation and amortization. Management defines Segment EBITDA as segment operating income before income tax expense, interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, and restructuring and divestiture-related and other costs. Management also defines Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, and the income tax impact of the aforementioned adjustments.
The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.
7 BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, 2026 and December 31, 2025 (In thousands, except share and per share data) (Unaudited)
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 717,840 $ 88,370 equivalents Accounts receivable, net of allowance 1,216,377 989,719 for credit losses Inventories 671,590 815,180 Prepaid expenses and other current 159,950 118,592 assets Current assets held for — 882,189 sale Total current assets 2,765,757 2,894,050 Property and equipment, net of accumulated depreciation of $419,016 and $404,878 at 213,530 204,689 September 30, 2026 and December 31, 2025, respectively Goodwill 2,537,128 2,545,673 Intangible assets, net of accumulated 491,661 557,555 amortization Operating lease 169,977 171,632 right-of-use assets, net Other assets 88,568 39,712 Total assets $ 6,266,621 $ 6,413,311 Liabilities, Redeemable Noncontrolling Interests, and Equity Current liabilities: Trade accounts payable $ 1,232,288 $ 1,217,946 Accrued expenses 390,967 333,024 Current portion of obligations under 46,296 42,936 operating leases Current portion of obligations under 5,988 6,794 financing leases Current portion of 35,277 52,340 long-term debt Current liabilities held — 195,994 for sale Total current 1,710,816 1,849,034 liabilities Obligations under operating leases, net 133,569 135,420 of current portion Obligations under financing leases, net 11,072 14,544 of current portion Long-term debt, net of 2,146,779 2,455,204 current portion Deferred income taxes, 10,336 6,178 net Long-term liabilities 68,234 66,565 Total liabilities 4,080,806 4,526,945 Redeemable 9,200 11,227 noncontrolling interests Shareholders’ equity: Common stock, $0.01 par value, 1,500,000,000 shares authorized, 198,814,320 and 192,124,125 shares $ 1,988 $ 1,921 issued and outstanding at September 30, 2026 and December 31, 2025 respectively Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and — — outstanding at September 30, 2026 and December 31, 2025 Additional paid-in 2,021,881 1,954,482 capital Retained earnings 138,572 (74,647 ) (accumulated deficit) Accumulated other comprehensive income 14,099 (6,691 ) (loss) Total shareholders’ 2,176,540 1,875,065 equity Noncontrolling interest 75 74 Total equity 2,176,615 1,875,139 Total liabilities, redeemable $ 6,266,621 $ 6,413,311 noncontrolling interests, and equity
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Statements of Operations For the three and nine months ended September 30, 2026 and 2025 (In thousands, except per share amounts) (Unaudited)
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows For the three and nine months ended September 30, 2026 and 2025 (In thousands) (Unaudited)
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Segment EBITDA For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles net income from continuing operations to Segment EBITDA:
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of EBITDA and Adjusted EBITDA For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles net income from continuing operations to EBITDA and Adjusted EBITDA:
(1) Represents non-cash share-based compensation to certain members of our management and full-time employees. (2) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. (3) Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Adjusted EPS For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles diluted EPS to Adjusted EPS:
(1) This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA. (2) The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non- GAAP adjustment. For all periods presented, the income tax impact on adjustments is inclusive of a discrete tax benefit related to share-based compensation.
Full text with the tables
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results
and Increases Full Year 2026 Guidance LOUISVILLE, Ky., October 30, 2026 —
BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ:
BTSG), a leading provider of home- and community-based health services for
complex populations, today announced financial results for the third quarter
ended September 30, 2026, and increased full year 2026 Revenue and Adjusted
EBITDA 1 guidance. Third Quarter 2026 Financial Highlights (note: On March 30,
2026, BrightSpring completed the divestiture of the Community Living business
and, as such, all financial results provided pertain to continuing operations) •
Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third
quarter of 2025 • Gross profit of $519 million, up 32.3% compared to $392
million in the third quarter of 2025 • Net income from continuing operations of
$101 million compared to $38 million in the third quarter of 2025 • Adjusted
EBITDA 1 of $228 million, up 42.0% compared to $160 million in the third quarter
of 2025 • Leverage of 1.79x as of September 30, 2026, compared to leverage of
2.15x on June 30, 2026 "Our third quarter results again reflect the commitment
of our team to patient care and operational execution across our Pharmacy and
Provider businesses," said Jon Rousseau, Chairman, President, and Chief
Executive Officer of BrightSpring. "We have a differentiated company, our value
proposition for healthcare stakeholders is clear, and our confidence in the
future remains high, supported by a broad set of process and growth drivers
across a uniquely scaled and high-quality platform. As we progress through 2026,
we believe that BrightSpring is well -positioned to make a greater and greater
impact and deliver durable growth in 2027 and beyond." 1 Adjusted EBITDA is a
non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the
end of this press release for a reconciliation of Adjusted EBITDA to net income
from continuing operations, the most directly comparable financial measure
prepared in accordance with GAAP. Key Financials 2
Three Nine
Months Months
Ended Ended
September September
30, 30,
(Unaudite… (Unaudite…
2026 2025 % 2026 2025 %
($ in
millions)
Pharmacy $
Solutions 3,732 $ 2,967 26% $ 10,311 $ 8,289 24%
Revenue
Provider
Services 481 367 31% 1,389 1,071 30%
Revenue
Total $ $ 3,334 26% $ 11,700 $ 9,360 25%
Revenue 4,213
1
Three Nine
Months Months
Ended Ended
September September
30, 30,
(Unaudite… (Unaudite…
2026 2025 % 2026 2025 %
($ in
million…
Pharmacy
Solutio… $ 202 $ 43% $ 551 $ 45%
Segment 141 381
EBITDA
Provider
Services 79 61 30% 220 168 31%
Segment
EBITDA
Total $ $
Segment $ 281 202 39% $ 771 550 40%
EBITDA(…
Corpora… -53 -41 n.m. -148 -116 n.m.
Costs
Total
Company $ 228 $ 42% $ 623 $ 44%
Adjusted 160 434
EBITDA(…
*n.m.: not meaningful Business Metrics
Three Nine
Months Months
Ended Ended
September September
30, 30,
(Unaudite… (Unaudite…
2026 2025 % 2026 2025 %
Pharmacy
Solutions
Prescrip… 10,949,875 10,793,219 2% 32,523,789 32,522,2… 0%
dispensed
Revenue
per 340.86 274.89 24% 317.03 254.88 24%
script
($)
Gross
Profit
per 28.86 22.76 27% 28.13 21.01 34%
script
($)
Provider
Services
Home
Health
Care 47,256 29,980 58% 46,898 30,212 55%
average
daily
census(3)
Rehab
Care 7,574 6,932 9% 7,345 6,806 8%
persons
served(3)
Personal
Care 16,320 16,134 1% 16,253 16,046 1%
persons
served
1 Adjusted EBITDA and Segment EBITDA are non-GAAP financial measures. Please see
“Non-GAAP Financial Information” and the end of this press release for a
reconciliation of Adjusted EBITDA and Segment EBITDA to net income from
continuing operations, the most directly comparable financial measure prepared
in accordance with GAAP. 2 Financial tables may not foot due to rounding. 3
Effective July 1, 2026, the Company realigned its Rehab in Motion business from
the Rehab Care sub-segment to the Home Health Care sub-segment to reflect how
the business is managed. Prior period sub-segment information has been recast to
conform to the current presentation. The change did not affect consolidated
company or segment results. The impact on prior periods was not material.
2
Full Year 2026 Financial Guidance
For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA
guidance, which excludes the Community Living business and the effects of any
future closed acquisitions. All growth rates are shown as compared to the full
year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living
business:
Revenues of $15,900 million to $16,125 million, or 23.2% to 24.9% growth
Pharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to
24.1% growth
Provider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4%
growth
Total Adjusted EBITDA 3 of $850 million to $860 million, or 37.6% to 39.3%
growth
The Amedisys and LHC branches acquisition is expected to contribute
approximately $35 million in Adjusted EBITDA in 2026
3A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted
EBITDA to GAAP net income from continuing operations cannot be provided without
unreasonable effort because of the inherent difficulty of accurately forecasting
the occurrence and financial impact of the various adjusting items necessary for
such reconciliation that have not yet occurred, are out of our control, or
cannot be reasonably predicted. For the same reasons, the Company is unable to
assess the probable significance of the unavailable information, which could
have a material impact on its future GAAP financial results.
Webcast and Conference Call Details
The Company will host a conference call today, October 30that 8:30 a.m. Eastern
Time. Investors interested in listening to the conference call are required
toregister online.
A live and archived webcast of the event will be available on the “Events &
Presentations” section of the BrightSpring website
athttps://ir.brightspringhealth.com/. The Company has posted supplemental
information on the third quarter 2026 results that it will reference during the
conference call. The supplemental information can be found under the “Events &
Presentations” on the Company’s investor relations page.
About BrightSpring Health Services
BrightSpring Health Services provides complementary home- and community-based
health solutions for medically complex populations in need of specialized and/or
chronic care. Through the Company’s service lines, including pharmacy, home
health care, and rehabilitation, we provide comprehensive and more integrated
care and clinical solutions in all 50 states to approximately 500,000 customers,
clients and patients daily. BrightSpring has consistently demonstrated strong
and industry-leading quality metrics across its services lines, while improving
the health and quality of life for high-need individuals and reducing overall
healthcare system costs.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views with respect to, among other things, our
operations and financial performance. Forward-looking statements include all
statements that are not historical facts. These forward-looking statements may
relate to matters which include, but are not limited to, industries, business
strategy, goals and expectations concerning our market position, future
operations, margins, profitability, capital expenditures, liquidity and capital
resources and other financial and operating
3
information. In some cases, we have used words such as “anticipate,” “assume,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,”
“target,” “guidance,” the negative version of these words, or similar terms and
phrases to identify these forward-looking statements.
The forward-looking statements are based on management’s current expectations
and are not historical facts or guarantees of future performance. The forward-
looking statements relate to the future and are therefore subject to various
risks, uncertainties, assumptions, or changes in circumstances that are
difficult to predict or quantify. Our expectations, beliefs, and projections are
expressed in good faith and we believe there is a reasonable basis for them.
However, there can be no assurance that management’s expectations, beliefs, and
projections will result or be achieved. Actual results may differ materially
from these expectations due to changes in global, regional, or local economic,
business, competitive, market, regulatory, and other factors, many of which are
beyond our control. We believe that these factors include but are not limited to
the following:
our operation in a highly competitive industry;
our inability to maintain relationships with existing patient referral sources
or establish new referral sources;
changes to Medicare and Medicaid rates or methods governing Medicare and
Medicaid payments for our services;
cost containment initiatives of third-party payors, including post-payment
audits;
the implementation of alternative payment models and the transition of Medicaid
and Medicare beneficiaries to managed care organizations may limit our market
share and could adversely affect our revenues;
changes in the case mix of patients, as well as payor mix and payment
methodologies, and decisions and operations of third-party organizations;
our reliance on federal and state spending, budget decisions, and continuous
governmental operations which may fluctuate under different political
conditions;
changes in drug utilization and/or pricing, PBM contracts, and Medicare Part
D/Medicaid reimbursement, which may negatively impact our profitability;
changes in our relationships with pharmaceutical suppliers, including changes in
drug availability or pricing;
reliance on the continual recruitment and retention of nurses, pharmacists,
therapists, caregivers, direct support professionals, and other qualified
personnel, including senior management;
compliance with or changes to federal, state, and local laws and regulations
that govern our employment practices, including minimum wage, living wage, and
paid time-off requirements;
fluctuation of our results of operations on a quarterly basis;
harm caused by labor relation matters;
limitations in our ability to control reimbursement rates received for our
services if we are unable to maintain or reduce our costs to provide such
services;
delays in collection or non-collection of our accounts receivable, particularly
during the business integration process;
failure to manage our growth effectively, which may inhibit our ability to
execute our business plan, maintain high levels of service and satisfaction or
adequately address competitive challenges;
our ability to identify, successfully complete and manage acquisitions, joint
ventures, divestitures and other significant transactions and strategic
initiatives;
our ability to continue to provide consistently high quality of care;
4
maintenance of our corporate reputation or the emergence of adverse publicity,
including negative information on social media or changes in public perception
of our services;
contract continuance, expansion and renewal with our existing customers,
including renewals at lower fee levels, customers declining to purchase
additional services from us, or reduction in the services received from us
pursuant to those contracts;
effective investment in, implementation of improvements to and proper
maintenance of the uninterrupted operation and data integrity of our information
technology and other business systems;
security breaches, loss of data, and other disruptions, which could compromise
sensitive business or patient information; cause a loss of confidential patient
data, employee data or personal information; or prevent access to critical
information and thereby expose us to liability, litigation, and federal and
state governmental inquiries and damage our reputation and brand;
risks related to credit card payments and other payment methods;
potential substantial malpractice or other similar claims;
various risks related to governmental inquiries, regulatory actions, and
whistleblower and other lawsuits, which may not be entirely covered by
insurance;
our current insurance program, which may expose us to unexpected costs,
particularly if we incur losses not covered by our insurance or if claims or
losses differ from our estimates;
factors outside of our control, including those listed, which have required and
could in the future require us to record an asset impairment of goodwill;
a pandemic, epidemic, or outbreak of an infectious disease;
inclement weather, natural disasters, acts of terrorism, riots, civil
insurrection or social unrest, looting, protests, strikes, or street
demonstrations;
our inability to adequately protect our intellectual property rights;
risks related to our compliance with our regulatory framework;
the significant interests of KKR Stockholder may conflict with our stockholders’
interests in the future;
our substantial indebtedness;
significant changes in tax or trade policies, tariffs, or trade relations
between the United States and other countries, such as the imposition of
unilateral tariffs on imported products, including impacts on imported drug
products, which could result in supply chain disruptions and significant
increases in costs; and
fluctuations in the amount and frequency of repurchases of our common stock.
The forward-looking statements included in this press release are made only as
of the date of this press release, and we undertake no obligation to publicly
update or revise any forward-looking statement, whether as a result of new
information, future developments, or otherwise, except as required by law. These
factors should not be construed as exhaustive, and should one or more of these
risks or uncertainties materialize, or should any of our assumptions prove
incorrect, our actual results may vary in material respects from those projected
in these forward-looking statements. Factors or events that could cause our
actual results to differ may emerge from time to time, and it is not possible
for us to predict all of them. We may not actually achieve the plans,
intentions, or expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements. Our forward-
looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures, investments, or other
strategic transactions we may make.
For additional information on these and other factors that could cause
BrightSpring’s actual results to differ materially from expected results, please
see our filings with the Securities and Exchange Commission (the “SEC”), which
are accessible on the SEC’s website atwww.sec.gov.
5
Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” including “EBITDA,”
“Segment EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial
measures that either exclude or include amounts that are not excluded or
included in the most directly comparable measures calculated and presented in
accordance with accounting principles generally accepted in the United States,
or GAAP.
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in
this release as supplemental measures of financial performance that are not
required by, or presented in accordance with, GAAP, because we believe they
assist investors and analysts in comparing our operating performance across
reporting periods on a consistent basis by excluding items that we do not
believe are indicative of our core operating performance. Management also
believes that these measures are useful to investors in highlighting trends in
our operating performance, while other measures can differ significantly
depending on long-term strategic decisions regarding capital structure, the tax
jurisdictions in which we operate and capital investments. Management uses
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP
measures of performance in the evaluation of the effectiveness of our business
strategies, to make budgeting decisions, to establish and award discretionary
annual incentive compensation, and to compare our performance against that of
other peer companies using similar measures.
Management supplements GAAP results with non-GAAP financial measures to provide
a more complete understanding of the factors and trends affecting the business
than GAAP results alone. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted
EPS are non-GAAP measures of our financial performance and should not be
considered as an alternative to net income as a measure of financial performance
or any other performance measures derived in accordance with GAAP. Additionally,
these measures are not intended to be a measure of free cash flow available for
management’s discretionary use as they do not consider certain cash requirements
such as tax payments, debt service requirements, total capital expenditures, and
certain other cash costs that may recur in the future.
Management defines EBITDA as net income from continuing operations before income
tax expense, interest expense, net and depreciation and amortization. Management
defines Segment EBITDA as segment operating income before income tax expense,
interest expense, net and depreciation and amortization. Management also defines
Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based
compensation, acquisition, integration and transaction-related costs, and
restructuring and divestiture-related and other costs. Management also defines
Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based
compensation, acquisition, integration and transaction-related costs,
restructuring and divestiture-related and other costs, and the income tax impact
of the aforementioned adjustments.
The presentations of these measures have limitations as analytical tools and
should not be considered in isolation, or as a substitute for analysis of our
results as reported under GAAP. Because not all companies use identical
calculations, the presentations of these measures may not be comparable to other
similarly titled measures of other companies and can differ significantly from
company to company. Please see the end of this press release for reconciliations
of non-GAAP financial measures to the most directly comparable financial measure
prepared in accordance with GAAP.
6
BrightSpring Contact:
Investor Relations:
David Deuchler, CFA
SVP, Strategic Finance & Investor Relations
Executive Director, BrightSpring Health Foundation
[email protected]
917.209.5605
Media Contact:Leigh White
Vice President, Communications & PR
[email protected]
502.630.7412
7
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Balance Sheets September 30, 2026 and December 31, 2025 (In thousands, except
share and per share data) (Unaudited)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash $ 717,840 $ 88,370
equivalents
Accounts receivable, net
of allowance 1,216,377 989,719
for credit losses
Inventories 671,590 815,180
Prepaid expenses and
other current 159,950 118,592
assets
Current assets held for — 882,189
sale
Total current assets 2,765,757 2,894,050
Property and equipment,
net of accumulated
depreciation of $419,016
and $404,878 at 213,530 204,689
September 30, 2026 and
December 31, 2025,
respectively
Goodwill 2,537,128 2,545,673
Intangible assets, net
of accumulated 491,661 557,555
amortization
Operating lease 169,977 171,632
right-of-use assets, net
Other assets 88,568 39,712
Total assets $ 6,266,621 $ 6,413,311
Liabilities, Redeemable
Noncontrolling
Interests, and Equity
Current liabilities:
Trade accounts payable $ 1,232,288 $ 1,217,946
Accrued expenses 390,967 333,024
Current portion of
obligations under 46,296 42,936
operating leases
Current portion of
obligations under 5,988 6,794
financing leases
Current portion of 35,277 52,340
long-term debt
Current liabilities held — 195,994
for sale
Total current 1,710,816 1,849,034
liabilities
Obligations under
operating leases, net 133,569 135,420
of current portion
Obligations under
financing leases, net 11,072 14,544
of current portion
Long-term debt, net of 2,146,779 2,455,204
current portion
Deferred income taxes, 10,336 6,178
net
Long-term liabilities 68,234 66,565
Total liabilities 4,080,806 4,526,945
Redeemable 9,200 11,227
noncontrolling interests
Shareholders’ equity:
Common stock, $0.01 par
value, 1,500,000,000
shares authorized,
198,814,320 and
192,124,125 shares $ 1,988 $ 1,921
issued and outstanding
at September 30, 2026
and December 31, 2025
respectively
Preferred stock, $0.01
par value, 250,000,000
authorized, no shares
issued and — —
outstanding at September
30, 2026 and December
31, 2025
Additional paid-in 2,021,881 1,954,482
capital
Retained earnings 138,572 (74,647 )
(accumulated deficit)
Accumulated other
comprehensive income 14,099 (6,691 )
(loss)
Total shareholders’ 2,176,540 1,875,065
equity
Noncontrolling interest 75 74
Total equity 2,176,615 1,875,139
Total liabilities,
redeemable $ 6,266,621 $ 6,413,311
noncontrolling
interests, and equity
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Statements of Operations For the three and nine months ended September 30, 2026
and 2025 (In thousands, except per share amounts) (Unaudited)
For For
the the
Three Nine
Mont… Mon…
Ended End…
Sept… Sep…
30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Pro… $ 3,73… $ 2,96… $ 10,3… $ 8,2…
Ser… 480,… 367,… 1,38… 1,0…
Tot… 4,21… 3,33… 11,7… 9,3…
rev…
Cost
of 3,41… 2,72… 9,39… 7,6…
goo…
Cost
of 278,… 220,… 810,… 648…
ser…
Gro… 518,… 392,… 1,49… 1,1…
pro…
Sel…
gen…
and 358,… 304,… 1,08… 918…
adm…
exp…
Ope… 160,… 87,8… 412,… 187…
inc…
Int…
exp… 31,0… 38,2… 106,… 118…
net
Inc…
from
con…
ope… 129,… 49,6… 305,… 68,…
bef…
inc…
tax…
Inc…
tax 28,6… 12,1… 44,0… 13,…
exp…
Inc…
from
con…
ope… 100,… 37,4… 261,… 55,…
net
of
inc…
tax…
(Lo…
inc…
from
dis…
ope… (503 ) 17,7… 71,4… 56,…
net
of
inc…
tax…
Net 100,… 55,2… 333,… 111…
inc…
Net
inc…
(lo…
att…
to
non… 161 (595 ) (77 ) (1,… )
int…
inc…
in
con…
ope…
Net
inc…
att…
to
Bri… $ 100,… $ 55,8… $ 333,… $ 113…
Hea…
Ser…
Inc.
and
sub…
Net
inc…
per
com…
sha…
Bas…
inc…
(lo…
per
sha…
att…
to
com…
sha…
Con… $ 0.49 $ 0.19 $ 1.27 $ 0.28
ope…
Dis… $ (0.01 ) $ 0.08 $ 0.35 $ 0.28
ope…
Net
inc… $ 0.48 $ 0.27 $ 1.62 $ 0.56
per
sha…
Dil…
inc…
(lo…
per
sha…
att…
to
com…
sha…
Con… $ 0.46 $ 0.17 $ 1.18 $ 0.26
ope…
Dis… $ (0.01 ) $ 0.09 $ 0.33 $ 0.26
ope…
Net
inc… $ 0.45 $ 0.26 $ 1.51 $ 0.52
per
sha…
Wei…
ave…
sha…
out…
Bas… 207,… 203,… 205,… 202…
Dil… 220,… 217,… 220,… 218…
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Statements of Cash Flows For the three and nine months ended September 30, 2026
and 2025 (In thousands) (Unaudited)
For For
the the
Three Nine
Mont… Mon…
Ended End…
Sept… Sep…
Ope… 30, 30,
act… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 100,… $ 55,2… $ 333,… $ 111…
inc…
Adj…
to
rec…
net
inc…
to
net
cash
pro…
by
ope…
act…
Dep…
and 38,3… 40,7… 118,… 124…
amo…
Imp…
of 5,195 2,507 8,240 6,5…
lon…
ass…
Cha…
in
fair
val… — (3,2… ) — (1,… )
of
con…
con…
net
Pay…
of
con…
con…
in
exc… — (4,6… ) — (6,… )
of
acq…
date
fair
val…
Pro…
for 5,829 8,065 28,6… 48,…
cre…
los…
Amo…
of
def… 2,553 2,841 8,317 8,3…
debt
iss…
cos…
Sha… 17,8… 17,2… 41,0… 55,…
com…
Def…
inc… 6,484 14,3… (3,0… ) 18,…
tax…
net
Loss
(ga…
on
sale 23 — (101… ) —
of
dis…
ope…
Oth… (771 ) (74 ) 243 (335 )
Cha…
in
ope…
ass…
and
lia…
net
of
acq…
and
dis…
Acc… (83,… ) (49,… ) (235… ) (16… )
rec…
Pre…
exp…
and 45,0… 446 (41,… ) 24,…
oth…
cur…
ass…
Inv… (96,… ) (13,… ) 143,… (2,… )
Tra…
acc… 142,… (10,… ) 54,9… 42,…
pay…
Acc… 19,2… 60,7… 47,1… 17,…
exp…
Oth…
ass… 1,687 (12,… ) (30,… ) (27… )
and
lia…
Net
cash
pro… $ 204,… $ 107,… $ 371,… $ 258…
by
ope…
act…
Inv…
act…
Pur…
of
pro… $ (22,… ) $ (15,… ) $ (72,… ) $ (57… )
and
equ…
Acq…
of (1,9… ) (1,5… ) (44,… ) (8,… )
bus…
Pro…
from
sale — — 810,… —
of
dis…
ope…
Oth… 827 (6,4… ) 1,893 (5,… )
Net
cash
(us…
in) $ (23,… ) $ (23,… ) $ 696,… $ (71… )
pro…
by
inv…
act…
Fin…
act…
Lon…
debt (11,… ) (14,… ) $ (332… ) $ (37… )
rep…
Rep…
of
the
Rev… — — — (63… )
Cre…
Fac…
net
Pay…
of
debt — — (3,3… ) —
iss…
cos…
Rep…
of
sha… — — (120… ) —
of
com…
sto…
Pro…
from
sha…
iss… 4,841 5,619 37,2… 14,…
und…
sha…
com…
plan
Tax…
paid
rel…
to
net (4,9… ) (1,0… ) (11,… ) (5,… )
sha…
set…
of
equ…
awa…
Pur…
of
red… — — (267 ) (5,… )
non…
int…
Pay…
of
fin… (1,7… ) (3,4… ) (7,5… ) (10… )
lea…
obl…
Net
cash
used $ (13,… ) $ (13,… ) $ (437… ) $ (10… )
in
fin…
act…
Net
inc…
in
cash 167,… 71,0… 629,… 80,…
and
cash
equ…
Cash
and
cash
equ… 550,… 70,2… 88,4… 61,…
at
beg…
of
per…
Cash
and
cash
equ… $ 717,… $ 141,… $ 717,… $ 141…
at
end
of
per…
Cash
and
cash
equ…
inc…
in
ass… — 956 — 956
held
for
sale
at
end
of
per…
Cash
and
cash
equ…
inc…
in $ 717,… $ 140,… $ 717,… $ 140…
con…
ope…
at
end
of
per…
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Segment
EBITDA For the three and nine months ended September 30, 2026 and 2025
(Unaudited) The following table reconciles net income from continuing operations
to Segment EBITDA:
For
For the the
Three Nine
Months Months
($ in Ended Septe… Ended Septem…
thou… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
inco…
from $ 100,8… $ 37,488 $ 261,689 $ 55,245
cont…
oper…
Segm…
depr… 30,794 33,791 97,367 102,2…
and
amor…
Expe…
not
allo…
at
segm…
leve…
Sell…
gene…
and 82,080 73,060 239,681 239,0…
admi…
expe…
Depr…
and 7,578 6,962 21,522 21,149
amor…
Inte…
expe… 31,038 38,235 106,532 118,7…
net
Inco…
tax 28,640 12,120 44,099 13,118
expe…
Total
Segm… $ 280,9… $ 201,656 $ 770,890 $ 549,6…
EBIT…
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of EBITDA and
Adjusted EBITDA For the three and nine months ended September 30, 2026 and 2025
(Unaudited) The following table reconciles net income from continuing operations
to EBITDA and Adjusted EBITDA:
For
For the the
Three Nine
Months Months
($ in Ended Septe… Ended Septem…
thou… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
inco…
from $ 100,8… $ 37,488 $ 261,689 $ 55,245
cont…
oper…
Inco…
tax 28,640 12,120 44,099 13,118
expe…
Inte…
expe… 31,038 38,235 106,532 118,7…
net
Depr…
and 38,372 40,753 118,889 123,4…
amor…
EBIT… $ 198,8… $ 128,596 $ 531,209 $ 310,5…
Non-…
shar… 17,871 14,173 50,475 46,155
comp…
(1)
Acqu…
inte…
and 2,855 5,462 15,585 34,811
tran…
costs
(2)
Rest…
and
dive…
and 8,181 12,212 25,756 42,493
other
costs
(3)
Total $ 28,907 $ 31,847 $ 91,816 $ 123,4…
adju…
Adju… $ 227,7… $ 160,443 $ 623,025 $ 434,0…
EBIT…
(1) Represents non-cash share-based compensation to certain members of our
management and full-time employees. (2) Represents transaction costs incurred in
connection with planned, completed, or terminated acquisitions, which include
investment banking fees, legal diligence and related documentation costs,
finance and accounting diligence and documentation; costs associated with the
integration of acquisitions, including any facility consolidation, integration
travel, or severance; and costs associated with other planned, completed, or
terminated non-routine transactions. (3) Represents costs associated with
restructuring-related activities, including closure, and related license
impairment, and severance expenses associated with certain enterprise-wide or
significant business line cost-savings measures.
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Adjusted
EPS For the three and nine months ended September 30, 2026 and 2025 (Unaudited)
The following table reconciles diluted EPS to Adjusted EPS:
For For
the the
Three Nine
(sh… Mont… Mon…
in Ended Sept… End… Sept…
tho… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Dil… $ 0.46 $ 0.17 $ 1.18 $ 0.26
EPS
Non…
sha… 0.08 0.07 0.23 0.21
com…
(1)
Acq…
int…
and 0.01 0.03 0.07 0.16
tra…
cos…
(1)
Res…
and
div…
and 0.04 0.06 0.12 0.19
oth…
cos…
(1)
Inc…
tax
imp… (0.05 ) (0.03 ) (0.23 ) (0.… )
on
adj…
(2)
Adj… $ 0.54 $ 0.30 $ 1.37 $ 0.69
EPS
Wei…
ave…
com…
sha…
out…
used
in
cal… 220,… 217,… 220,… 218…
dil…
U.S.
GAAP
net
inc…
per
sha…
Wei…
ave…
com…
sha…
out…
used
in 220,… 217,… 220,… 218…
cal…
dil…
Non…
inc…
per
sha…
(1) This adjustment reflects the per share impact of the adjustment reflected
within the definition of Adjusted EBITDA. (2) The income tax impact of non-GAAP
adjustments is calculated using the estimated tax rate for the respective non-
GAAP adjustment. For all periods presented, the income tax impact on adjustments
is inclusive of a discrete tax benefit related to share-based compensation.